Invention Grant
- Patent Title: Antibodies specific to human NECTIN4
-
Application No.: US17052960Application Date: 2019-05-06
-
Publication No.: US12077583B2Publication Date: 2024-09-03
- Inventor: Ofer Mandelboim , Adi Reches , Stipan Jonjic , Pinchas Tsukerman
- Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. , NECTIN THERAPEUTICS LTD.
- Applicant Address: IL Jerusalem
- Assignee: NECTIN THERAPEUTICS LTD.,YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
- Current Assignee: NECTIN THERAPEUTICS LTD.,YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
- Current Assignee Address: IL Jerusalem; IL Jerusalem
- Agency: RAPHAEL BELLUM PLLC
- Agent Stephen C. Bellum
- International Application: PCT/IL2019/050508 2019.05.06
- International Announcement: WO2019/215728A 2019.11.14
- Date entered country: 2020-11-04
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K45/06 ; A61P35/00 ; C07K16/28 ; A61K39/00
Abstract:
The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.
Public/Granted literature
- US20210130459A1 ANTIBODIES SPECIFIC TO HUMAN NECTIN4 Public/Granted day:2021-05-06
Information query
